The structure-antituberculosis activity relationships study in a series of 5-aryl-2-thio-1,3,4-oxadiazole derivatives

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 22, 2011, Pages 6792-6807

  MacAev, Fliur ^a   Ribkovskaia, Zinaida ^a   Pogrebnoi, Serghei ^a   Boldescu, Veaceslav ^a   Rusu, Ghenadie ^a   Shvets, Nathaly ^b   Dimoglo, Anatholy ^b   Geronikaki, Athina ^c   Reynolds, Robert ^d  

^a INSTITUTE OF CHEMISTRY   (Moldova)

^b GEBZE TECHNICAL UNIVERSITY   (Turkey)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Antituberculosis activity; Docking; Electronic topological method; Neural networks; Structure activity relationships

Indexed keywords

1 (2,4 DICHLOROPHENYL) 2 [5 (3 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOL 2 YLSULFANYL] 1 ETHANONE; 1 (2,4 DICHLOROPHENYL) 2 [5 (4 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOL 2 YLSULFANYL] 1 ETHANONE; 1 (4 BROMOPHENYL) 2 [5 (3 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOL 2 YLSULFANYL] 1 ETHANONE; 1 (4 CHLOROPHENYL) 2 [5 (3 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOL 2 YLSULFANYL] 1 ETHANONE; 1 (4 FLUOROPHENYL) 2 [5 (3 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOL 2 YLSULFANYL] 1 ETHANONE; 1 (4 FLUOROPHENYL) 2 [5 (4 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOL 2 YLSULFANYL] 1 ETHANONE; 2 (2 PYRIMIDINYLSULFANYL) 5 (4 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOLE; 2 (4 PYRIDYLMETHYLSULFANYL) 5 (4 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOLE; 2 [5 (3 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOL 2 YLSULFANYL] 1 (2 NAPHTHYL) 1 ETHANONE; 2 [5 (4 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOL 2 YLSULFANYL] 1 PHENYL 1 ETHANONE; 2 ALLYLSULFANYL 5 (3 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOLE; 2 ALLYLSULFANYL 5 (4 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOLE; 2 BENZYLSULFANYL 5 (3 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOLE; 2 BENZYLSULFANYL 5 (4 ISOTHIOCYANATOPHENYL) 1,3,4 OXADIAZOLE; 2 HYDROXYETHYLAMINO 4 (5 SULFANYL 1,3,4 OXADIAZOL 2 YL)ANILINOMETHANETHIONE; 4 (5 SULFANYL 1,3,4 OXADIAZOL 2 YL)ANILINO 4 TOLUIDINOMETHANETHIONE; 5 (3 ISOTHIOCYANATOPHENYL) 2 PHENYLETHYLSULFANYL 1,3,4 OXADIAZOLE; 5 (4 ISOTHIOCYANATOPHENYL) 2 METHYLSULFANYL 1,3,4 OXADIAZOLE; 5 ARYL 2 THIO 1,3,4 OXADIAZOLE DERIVATIVE; ALLYLAMINO 4 (5 SULFANYL 1,3,4 OXADIAZOL 2 YL)ANILINOMETHANETHIONE; AMINO 4 (5 SULFANYL 1,3,4 OXADIAZOL 2 YL)ANILINOMETHANETHIONE; ETHYLAMINO 4 (5 SULFANYL 1,3,4 OXADIAZOL 2 YL)ANILINOMETHANETHIONE; HYDRAZINO 4 (5 METHYLSULFANYL 1,3,4 OXADIAZOL 2 YL)ANILINOMETHANETHIONE; HYDRAZINO 4 (5 SULFANYL 1,3,4 OXADIAZOL 2 YL)ANILINOMETHANETHIONE; METHYLAMINO 4 (5 SULFANYL 1,3,4 OXADIAZOL 2 YL)ANILINOMETHANETHIONE; N [4 (5 MERCAPTO 1,3,4 OXADIAZOL 2 YL)PHENYL] 2,2 DIMETHYLHYDRAZINECARBOTHIOAMIDE; PIPERIDINO 4 (5 SULFANYL 1,3,4 OXADIAZOL 2 YL)ANILINOMETHANETHIONE; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; GROWTH INHIBITION; MYCOBACTERIUM TUBERCULOSIS; PHARMACOPHORE; PREDICTION; STRUCTURE ACTIVITY RELATION;

ANTITUBERCULAR AGENTS; CATALYTIC DOMAIN; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MYCOBACTERIUM TUBERCULOSIS; OXADIAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

MYCOBACTERIUM TUBERCULOSIS;

EID: 80054996638     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.09.038     Document Type: Conference Paper

References (46)

1. Y.L. Janin Bioorg. Med. Chem. 15 2007 2479
2. Murray, J.L. Christopher, Lopez, and D. Alan The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020: Summary 1996 WHO Switzerland
3. J.P. Narain Tuberculosis-Epidemiology and Control Vol. 248 2002 World Health Organization New Delhi, India pp 15-18
4. L. Fattorini, E. Iona, M.L. Ricci, O.F. Thoresen, G. Orr, M.R. Oggioni, E. Tortoli, C. Piersimoni, P. Chiaradonna, M. Tronci, G. Pozzi, and G. Orefici Microb. Drug Resist. 5 1999 265
5. A. Van Rie, R.M. Warren, N. Beyers, R.P. Gie, C.N. Classen, M. Richardson, S.L. Sampson, T.C. Victor, and P.D. Van Helden J. Infect. Dis 180 1999 1608
6. G.C. Enwere, M.O. Ota, and S.K. Obaro Ann. Trop. Med. Parasitol. 93 1999 669
7. K. Smith, J. Bender, M. Osterholm, I. Nachamkin, and M. Blaser Campylobacter 2000 American Society for Microbiology Washingdon, DC pp 483-495
8. World Health Organization. In Antituberculosis Drug Resistance in the World; The WHO/IUALTD Global Project on Antituberculosis Drug Resistance Surveillance. Switzerland, 1997.
9. L. Ballell, R.A. Field, K. Duncan, and R.J. Young Antimicrob. Agents Chemother. 49 2005 2153
10. H.S. Sutherland, A. Blaser, I. Kmentova, S.G. Franzblau, B. Wan, Y. Wang, Z. Ma, B.D. Palmer, W.A. Denny, and A.M. Thompson J. Med. Chem. 53 2010 855
11. G. Navarrete-Vázquez, G.M. Molina-Salinas, Z.V. Duarte-Fajardo, J. Vargas-Villarreal, S. Estrada-Soto, F. González-Salazar, E. Hernández-Núñez, and S. Said-Fernández Bioorg. Med. Chem. 15 2007 5502
12. R.H. Khan, and R.C. Rastogi J. Agric. Food Chem. 38 1990 1068
13. B. Narayana, K.K.V. Raj, B.V. Ashalatha, and N.S. Kumari Arch. Pharm. Chem. Life Sci. 338 2005 373
14. T. Schelenz, J. Klunker, T. Bernhardt, W. Schafer, and J. Dost Quant. Struct.-Act. Relat. 20 2001 291
15. F. Macaev, G. Rusu, S. Pogrebnoi, A. Gudima, E. Stingaci, L. Vlad, N. Shvets, F. Kandemirli, A. Dimoglo, and R. Reynolds Bioorg. Med. Chem. 13 2005 4842
16. V. Klimesova, L. Zahajska, K. Waisser, J. Kaustova, and U. Möllmann Farmaco 59 2004 279
17. I. Mir, and M.T. Siddiqui Tetrahedron 26 1970 5235
18. N. Ulusoy, A. Gürsoy, and G. Ötük Farmaco 56 2001 947
19. S.A. Kaplancikli, G. Turan-Zitouni, and P. Chevallet J. Enzyme Inhib. Med. Chem. 20 2005 179
20. A. Dimoglo, V. Kovalishyn, N. Shvets, and V. Ahsen Mini-Rev. Med. Chem. 5 2005 879
21. A.S. Dimoglo, P.F. Vlad, N.. Shvets, and M.N. Coltsa N. J. Chem. 25 2001 283
22. A.S. Dimoglo, N.M. Shvets, I.V. Tetko, and D.J. Livingstone Quant. Struct.-Act. Relat. 20 2001 31
23. A. Dimoglo, E. Sim, N. Shvets, and V. Ahsen Mini-Rev. Med. Chem. 3 2003 293
24. E. Sim, A. Dimoglo, N. Shvets, and V. Ahsen Curr. Med. Chem. 9 2002 1537
25. E. Oru, S. Rollas, F. Kandemirli, N. Shvets, and A. Dimoglo J. Med. Chem. 47 2004 6760
26. B. Koyiit-Kaymakiolu, E. Oru, S. Unsalan, F. Kandemirli, N. Shvets, S. Rollas, and A. Dimoglo Eur. J. Med. Chem. 41 2006 1253
27. G.G. Rusu, E.E. Gutu, and N.A. Barba Russ. J. Org. Chem. 31 1995 1721
28. L. Collins, and S.G. Franzblau Antimicrob. Agents Chemother. 41 1997 1004
29. C.G. Wermuth The Practice of Medicinal Chemistry 1996 Academic Press San Diego pp 81-99
30. N.C. Cohen Guidebook on Molecular Modelling in Drug Design 1996 Academic Press San Diego p 361
31. PDB ID:1CI0. Shi, W.; Ostrov, D.A.; Gerchman, S.E.; Graziano, V.; Kycia, H.; Studier, B.; Almo, S.C.; Burley, S.K. New York Structural GenomiX Research Consortium (NYSGXRC).
32. B.K. Biswal, M.M. Cherney, M. Wang, C. Garen, and M.N. James Acta Crystallogr. D61 2005 1492
33. S. Canaan, G. Sulzenbacher, V. Roig-Zamboni, L. Scappuccini-Calvo, F. Frassinetti, D. Maurin, C. Cambillau, and Y. Bourne FEBS Lett. 579 2005 215
34. Molecular Operating Environment (MOE) software, release 2008.10.
35. M.J.S. Dewar, E.G. Zoebisch, E.F. Healy, and J.J.P. Stewart J. Am. Chem. Soc. 107 1985 3902
36. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. GAUSSIAN-03, Revision A.1, Gaussian; Pittsburgh, PA, 2003.
37. A.S. Dimoglo Khim. Pharm. Zhur. 4 1985 438
38. A.S. Dimoglo In Book 'Coordination and Organic Biologically Active Compounds' 1986 Kishinev pp 7-11
39. I.B. Bersuker, and A.S. Dimoglo K.B. Lipkowitz, D.B. Boyd, Reviews in Computational Chemistry 1991 VCH New-York Chapter 10
40. N.M. Shvets, and A.S. Dimoglo Nahrung 42 1998 364
41. R.D. Cramer, S.A. DePriest, D.E. Patterson, and P. Hecht H. Kubinyi, 3D QSAR in Drug Design: Theory Methods and Applications 1993 ESCOM: Leiden The Netherlands 443 486
42. I.V. Tetko J. Chem. Inf. Comput. Sci. 42 2002 717
43. I.V. Tetko, D.J. Livingstone, and A.I. Luik J. Chem. Inf. Comput. Sci. 35 1995 826
44. I.V. Tetko, V.V. Kovalishyn, and D.J. Livingstone J. Med. Chem. 44 2001 2411
45. I.V. Tetko, A.E.P. Villa, and D.J. Livingstone J. Chem. Inf. Comput. Sci. 36 1996 794
46. V.V. Kovalishyn, I.V. Tetko, A.I. Luik, V.V. Kholodovych, A.E.P. Villa, and D.J. Livingstone J. Chem. Inf. Comput. Sci. 38 1998 651